Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL684068 | 0.91 | ADORA2B (0.50) | MAPK1ADORA2BHTR2AHTR7 | |
| SCHEMBL683668 | 0.89 | ADORA2B (0.49) | ADORA2BHTR2ATNFGLABLM | |
| SCHEMBL684026 | 0.87 | MAPK1 (0.49) | MAPK1ADORA2BHTR2AHTR7HTR6 | |
| SCHEMBL683652 | 0.87 | MAPK1 (0.55) | MAPK1HTR2ATNFALDH1A1MAPT | |
| SCHEMBL684023 | 0.86 | HTR2A (0.58) | MAPK1ADORA2BHTR2AHTR7HTR6 | |
| SCHEMBL683657 | 0.84 | DRD2 (0.51) | MAPK1HTR2AHTR7ALDH1A1 | |
| SCHEMBL684005 | 0.83 | HTR7 (0.58) | MAPK1TNFHTR7HTR6ALDH1A1 | |
| SCHEMBL683665 | 0.82 | ADORA2B (0.47) | MAPK1ADORA2BHTR2ATNFSMN1; SMN2 | |
| SCHEMBL684375 | 0.82 | ADORA2B (0.53) | MAPK1ADORA2BHTR2AALDH1A1MAPT | |
| SCHEMBL683653 | 0.81 | ADRA1D (0.52) | MAPK1ADORA2BHTR2ATNFSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | MAPK1 470/4885ADORA2B 786/4885HTR2A 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.